• Sheraton New York Times Square Hotel (map)
  • 811 7th Avenue
  • New York, NY, 10019
  • United States

Session Chairs:  Glenn Dranoff, Novartis Institutes for BioMedical Research, Cambridge, MA, and Axel Hoos, GlaxoSmithKline Pharmaceuticals, Collegeville, PA

1:10 p.m.  Axel Hoos, GlaxoSmithKline Pharmaceuticals, Collegeville, PA
Introduction

1:30 p.m.  Christina M. Coughlin, Immunocore Limited, Philadelphia, PA
Immune mobilizing TCR therapies against cancer (ImmTAC): A novel class of antigen specific tumor immunotherapy

2:00 p.m.  Patrick A. Mayes, GlaxoSmithKline Pharmaceuticals, Collegeville, PA
Targeting inducible T cell co-stimulator (ICOS) promotes effector T cell function and anti-tumor response

2:30 p.m.  Juan C. Jaen, Arcus Biosciences, Inc., Hayward, CA
Small-molecule inhibitors of CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumors*

2:45 p.m.  Refreshment Break

3:15 p.m.  Viviana Cremasco, Novartis Institutes for BioMedical Research, Cambridge, MA
Microenvironmental regulation of anti-tumor immune responses: A lesson from fibroblastic cells

3:45 p.m.  Niels Halama, National Center for Tumor Diseases, Heidelberg, Germany
Macrophage repolarization therapy in metastatic colorectal cancer: CCR5 inhibition*

4:00 p.m.  David M. Reese, Amgen, Thousand Oaks, CA
New frontiers in oncolytic virus therapy

4:30 p.m.  K. Dane Wittrup, Massachusetts Institute of Technology, Cambridge, MA
Synergistic innate and adaptive integrin-targeted immunotherapy

* Proffered presentation